Drugs / Hyperbaric bupivacaine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT07651488 Comparator | Mar → Sep 2023 | — | Liaquat National Hospital & Medical College | Completed | No outcome recorded |
| Phase 3 | NCT02973048 Comparator | Mar → Nov 2018 | hypotensive disorder | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperbaric bupivacaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07651488 ↗ |
| Route | Intrathecal | “The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally” NCT02973048 ↗ |